Drug name review: Science takes the spotlight in 2022

Beth Snyder Bulik

Senior Editor

Science was the name of the game in pharma drugs last year — literally. FDA-approved drug names in 2022 leaned heavily on science associations, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drug name review: Science takes the spotlight in 2022

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Drug name re­view: Sci­ence takes the spot­light in 2022

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Drug name review: Science takes the spotlight in 2022